Trial Profile
A Two-Arm, Multi-Center Trial of Revlimid and Rituximab, for First-Line Treatment in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 13 Dec 2011 Results were presented at the 53rd Annual Meeting of the American Society of Hematology (ASH)
- 13 Dec 2011 Status changed from recruiting to completed.
- 06 May 2009 New source identified and integrated (M.D. Anderson Cancer Center).